Previous reports in non-SLE ITP populations have described venous and arterial thrombosis during TPO-RA therapy; therefore, clinicians should assess baseline thrombosis risk and monitor patients closely when using these agents in SLE. This evidence concerns the gene TPO and autoimmune thrombocytopenic purpura.